종목/ENGN
E
엔진 홀딩스
ENGNNasdaqCM· HealthcareenGene Therapeutics Inc.
$1.75
종가· 6. 27.
$117M
시가총액
$1.75
6. 27. 종가
시가총액
$117M
BEAT6월 15일 (월)장전실제값2026 Q2 실적 발표 결과
EPS 실제
$-0.43
예상 $-0.48
Surprise
+10.3%
매출
$0
발표 직후 반응
+9.3%
5일 +6.2%
최근 1분기:
·이번 분기는 Beat, 1연속 Beat 행진
동종업계 비교
Healthcare · 시총 상위기업 정보
섹터Healthcare
산업Biotechnology
대표이사—
상장일12월 10일 (금)
발행주식수67.0M주
직원수81명
웹사이트www.engene.com
회사 소개 보기
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
분기 실적 히스토리
최근 1분기| 발표일 | 분기 | EPS 예상 | EPS 실제 | Surprise | 매출 실제 | 발표 직후 반응 |
|---|---|---|---|---|---|---|
| 6월 15일 (월) | 2026 Q2 | $-0.48 | $-0.43 | +10.3% | $0 | ▲ 9.3% |